FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091202169> ?p ?o ?g. }

• W2091202169 endingPage "157" @default.
• W2091202169 startingPage "157" @default.
• W2091202169 abstract "Dear Sir,Isolated limb perfusion (ILP) was introduced in clinicalpractice in the 1950s and earlier studies using hyperthermicILP with melphalan for limb melanoma reported impressiveresultswithoverallresponse(OR)ratesof80%andcompleteresponse (CR) rates of 30 and-50% [1]. More recent reportsindicate that CR rates exceeding 50% are now obtained inmost melanoma treatment centres where ILP is undertaken[2]andevenhigherCRrateshavebeenreportedwhentumournecrosis factor (TNF) has been used with melphalan [3].We read with interest the paper by Romics in your June2011 issue utilising melphalan ± TNF alpha in patientswith unresectable melanoma of the limb and reporting anOR rate of 93% and CR rate of 67%. ILP is also undertakenin our unit and we recently audited our results which aresummarised below.From 1980 to 2001, 378 patients with limb malignantmelanoma underwent therapeutic ILPs at St Mary’s Hos-pital, London. 41 patients had ILP of the upper limb while337 had ILP of the lower limb (236 iliac ILP/101 femoralILP). We employed the melphalan and mitomycin C drugregimen. 284/378 patients had complete follow-up and ofthese 32% had a CR, 38% had [50% response, 25% had50% response and 6% had no response. There was a 13%leak rate in responders and 21% in non-responders. Therewas no postoperative mortality, while perioperative mor-bidity was seen in 50/284 patients (18%) and included limboedema (34), deep venous thrombosis (8), vascular damage(4) and transient nerve/muscle damage (2). 60% of ourpatients survived more than a year on 5-year follow-up.ILP is a technically demanding, costly and time-con-suming technique which should be undertaken in tertiaryreferral centres by experts. Limb amputation for nonresec-table disease can lead to stump recurrences which are diffi-cult to control and make the fitting of a prosthesischallenging. However, with good patient selection, ILP is avaluable therapeutic option and in our experience it is pref-erable to amputation as an effective therapeutic modality fornonresectable limb melanoma despite the significant risk ofregional and systemic complications and lack of an effect onsurvival.We, the undersigned, are pleased for an opportunity toreport our results to augment the ever-increasing pool ofknowledge relevant to this technique.References" @default.
• W2091202169 created "2016-06-24" @default.
• W2091202169 creator A5017336081 @default.
• W2091202169 creator A5057677840 @default.
• W2091202169 creator A5063593371 @default.
• W2091202169 creator A5080136936 @default.
• W2091202169 date "2011-09-29" @default.
• W2091202169 modified "2023-10-11" @default.
• W2091202169 title "Therapeutic isolated limb perfusion (ILP) in the management of patients with advanced or recurrent limb melanoma" @default.
• W2091202169 cites W1889451488 @default.
• W2091202169 cites W2063519460 @default.
• W2091202169 doi "https://doi.org/10.1007/s11845-011-0764-7" @default.
• W2091202169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21959950" @default.
• W2091202169 hasPublicationYear "2011" @default.
• W2091202169 type Work @default.
• W2091202169 sameAs 2091202169 @default.
• W2091202169 citedByCount "0" @default.
• W2091202169 crossrefType "journal-article" @default.
• W2091202169 hasAuthorship W2091202169A5017336081 @default.
• W2091202169 hasAuthorship W2091202169A5057677840 @default.
• W2091202169 hasAuthorship W2091202169A5063593371 @default.
• W2091202169 hasAuthorship W2091202169A5080136936 @default.
• W2091202169 hasBestOaLocation W20912021691 @default.
• W2091202169 hasConcept C126322002 @default.
• W2091202169 hasConcept C141071460 @default.
• W2091202169 hasConcept C146957229 @default.
• W2091202169 hasConcept C164705383 @default.
• W2091202169 hasConcept C2777658100 @default.
• W2091202169 hasConcept C2780690508 @default.
• W2091202169 hasConcept C2989316616 @default.
• W2091202169 hasConcept C502942594 @default.
• W2091202169 hasConcept C71924100 @default.
• W2091202169 hasConceptScore W2091202169C126322002 @default.
• W2091202169 hasConceptScore W2091202169C141071460 @default.
• W2091202169 hasConceptScore W2091202169C146957229 @default.
• W2091202169 hasConceptScore W2091202169C164705383 @default.
• W2091202169 hasConceptScore W2091202169C2777658100 @default.
• W2091202169 hasConceptScore W2091202169C2780690508 @default.
• W2091202169 hasConceptScore W2091202169C2989316616 @default.
• W2091202169 hasConceptScore W2091202169C502942594 @default.
• W2091202169 hasConceptScore W2091202169C71924100 @default.
• W2091202169 hasIssue "1" @default.
• W2091202169 hasLocation W20912021691 @default.
• W2091202169 hasLocation W20912021692 @default.
• W2091202169 hasOpenAccess W2091202169 @default.
• W2091202169 hasPrimaryLocation W20912021691 @default.
• W2091202169 hasRelatedWork W1639979835 @default.
• W2091202169 hasRelatedWork W1969505757 @default.
• W2091202169 hasRelatedWork W2002370461 @default.
• W2091202169 hasRelatedWork W2053096632 @default.
• W2091202169 hasRelatedWork W2153814163 @default.
• W2091202169 hasRelatedWork W2410278223 @default.
• W2091202169 hasRelatedWork W2415636878 @default.
• W2091202169 hasRelatedWork W2972244810 @default.
• W2091202169 hasRelatedWork W2997632039 @default.
• W2091202169 hasRelatedWork W4366782918 @default.
• W2091202169 hasVolume "181" @default.
• W2091202169 isParatext "false" @default.
• W2091202169 isRetracted "false" @default.
• W2091202169 magId "2091202169" @default.
• W2091202169 workType "article" @default.